← Back to Search

Cognitive Behavioral Therapy for Smoking Cessation in HIV/AIDS

N/A

Waitlist Available

Led By Jasper Smits, PhD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18-79 years old

Be older than 18 years old

Must not have

Cognitive behavioral therapy for anxiety within the past year

Untreated or unstable psychiatric disorders

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time frame: 6-month follow-up (approximately 6-months post quit date)

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a cognitive-behavioral-based intervention to help smokers living with HIV quit smoking by reducing anxiety and depression.

Who is the study for?

This trial is for HIV-positive individuals aged 18-79 who smoke daily and are motivated to quit. They must understand English well enough to give informed consent. People using other tobacco products, undergoing current smoking cessation treatment, or with untreated/unstable psychiatric disorders can't participate.

What is being tested?

The study tests a cognitive-behavioral-based intervention called QUIT against a Time-Matched Control (TM) to help smokers living with HIV quit by reducing anxiety and depression. It's a fully powered trial aiming to see if the intervention increases abstinence from smoking at 1-month and 6-month follow-ups.

What are the potential side effects?

While specific side effects are not listed for this behavioral intervention, participants may experience discomfort discussing personal issues or stress related to quitting smoking during the sessions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 79 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have undergone cognitive behavioral therapy for anxiety in the last year.

Select...

I do not have untreated or unstable mental health issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time frame: 6-month follow-up (approximately 6-months post quit date)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time frame: 6-month follow-up (approximately 6-months post quit date)

This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: 6-month follow-up (approximately 6-months post quit date) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Long-Term Point Prevalence Smoking Abstinence

Short-Term Point Prevalence Smoking Abstinence

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: QUIT Treatment for Smoking Cessation and Distress ToleranceExperimental Treatment1 Intervention

Participants in this intervention arm will receive a Cognitive-Behavioral therapy-based intervention for smoking cessation in people living with HIV.

Group II: Time and Intensity-Match ControlActive Control1 Intervention

Participants in this control arm will receive an intervention matched in time and intensity with the experimental arm.

Group III: Standard of CareActive Control1 Intervention

At each clinic, routine assessment of smoking status occurs at least annually for patients receiving care, but prescription for pharmacotherapy for smoking cessation and referral for behavioral smoking cessation services are rare. Patients will receive the standard of care at the clinic they attend. SOC patients will also attend the first session that participants in the other sessions receive (pre-randomization), will come to the clinic for assessment only during the weeks lining up with sessions 6-10 for the other conditions, and receive the transdermal nicotine patch for 8 weeks.

0 / 3Eligibility criteria met